Endothelial FSH receptor expression and vascular remodeling in hormone-refractory prostate cancer.

被引：0
|
作者：
Ghinea, Nicolae [1 ]
Robin, Blaise [1 ]
Planeix, Francois [1 ]
Brito, Isabel [1 ]
Pichon, Christophe [1 ]
机构：
[1] Inst Curie, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16035
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Satraplatin in the treatment of hormone-refractory prostate cancer
    Sternberg, CN
    BJU INTERNATIONAL, 2005, 96 (07) : 990 - 994
  • [42] Hormone-refractory prostate cancer: Therapeutic approach
    Pepe, A.
    Leonardi, V.
    Palmisano, V.
    Savio, G.
    Calabria, C.
    Laudani, A.
    Usset, A.
    Cusimano, M.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2005, 16 : 154 - 155
  • [43] DocetaxelIn Hormone-Refractory Metastatic Prostate Cancer
    Kate McKeage
    Susan J. Keam
    Drugs, 2005, 65 : 2287 - 2294
  • [44] The role of endothelin in hormone-refractory prostate cancer
    Zonnenberg, BA
    Voest, EE
    EUROPEAN UROLOGY SUPPLEMENTS, 2003, 2 (03) : 9 - 14
  • [45] Combination therapy in hormone-refractory prostate cancer
    Daniel P. Petrylak
    Current Oncology Reports, 2001, 3 (5) : 453 - 453
  • [46] Pyrazoloacridine for the treatment of hormone-refractory prostate cancer
    Small, EJ
    Fippin, LJ
    Whisenant, SP
    CANCER INVESTIGATION, 1998, 16 (07) : 456 - 461
  • [47] Hormone-refractory prostate cancer responding to bevacizumab
    Iacobelli, Stefano
    INTERNATIONAL JOURNAL OF UROLOGY, 2008, 15 (08) : 754 - 754
  • [48] Docetaxel and exisulind in hormone-refractory prostate cancer
    Ryan, CW
    Stadler, WM
    Vogelzang, NJ
    SEMINARS IN ONCOLOGY, 2001, 28 (04) : 56 - 61
  • [49] Future therapies in hormone-refractory prostate cancer
    Smith, MR
    Nelson, JB
    UROLOGY, 2005, 65 (5A) : 9 - 16
  • [50] Chemotherapy for the treatment of hormone-refractory prostate cancer
    Petrylak, DP
    EUROPEAN UROLOGY SUPPLEMENTS, 2002, 1 (02) : 15 - 23
12345